Kosuke Tanaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kosuke Tanaka has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Akifumi Kuwano
Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan
5 shared publicationsKenta Motomura
Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan
5 shared publicationsMasayoshi Yada
Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan
4 shared publicationsAkihide Masumoto
Department of Hepatology, Aso Iizuka Hospital, Iizuka, Fukuoka 820‑8505, Japan
3 shared publicationsShigehiro Nagasawa
Department of Hepatology, Aso Iizuka Hospital, Iizuka, Fukuoka 820‑8505, Japan
3 shared publications- Akifumi Kuwano
Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan
2 shared publications
Latest Publications
- 28 April 2026
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46 (5) , 2609-2618
Identification of Risk Factors for the Local Recurrence of Hepatocellular Carcinoma Post-radiofrequency Ablation
Radiofrequency ablation (RFA) is a mainstay curative treatment for unresectable hepatocellular carcinoma (HCC). Despite the success of RFA, however, some patients with HCC continue to experience local recurrence (LR). The aim of the present study was to identify risk factors for LR post-RFA, considering cases of repeated RFA for LR-HCC separately. This study initially included 829 patients who underwent RFA for HCC at our institution between January 2013 and December 2022. From these, 447 patients with single HCC were selected based on the selection criteria, and they were further classified into a new HCC lesion group (n=400, NL group) and repeated RFA for LR-HCC post-first RFA group (n=47, LR group). The two groups were retrospectively analyzed to identify factors related to LR post-RFA. In the NL and LR groups, the median observation period after treatment was 36.9 months and 33.7 months, respectively. The cumulative LR rates were 5.1%, 11.0%, and 14.2% in the NL group, and 12.8%, 34.2%, and 40.8% in LR group at 1, 3, and 5 years post-RFA, respectively. The Cox proportional hazard test showed that HCC tumors >1.5 cm [hazard ratio (HR)=3.606; p=0.001] and tumor site (adjacent to blood vessels) (HR=1.932; p=0.035) were identified as independent risk factors for LR post-RFA in the NL group, while only TACE prior to RFA was identified in the LR group. Tumor size and site of HCC were independent risk factors for LR post-RFA. Moreover, repeated RFA for LR-HCC post-first RFA had quite a high rate of LR post-RFA. For these cases, the selection of modalities other than RFA should be considered.
- 28 April 2026
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46 (5) , 2609-2618
Identification of Risk Factors for the Local Recurrence of Hepatocellular Carcinoma Post-radiofrequency Ablation
Radiofrequency ablation (RFA) is a mainstay curative treatment for unresectable hepatocellular carcinoma (HCC). Despite the success of RFA, however, some patients with HCC continue to experience local recurrence (LR). The aim of the present study was to identify risk factors for LR post-RFA, considering cases of repeated RFA for LR-HCC separately. This study initially included 829 patients who underwent RFA for HCC at our institution between January 2013 and December 2022. From these, 447 patients with single HCC were selected based on the selection criteria, and they were further classified into a new HCC lesion group (n=400, NL group) and repeated RFA for LR-HCC post-first RFA group (n=47, LR group). The two groups were retrospectively analyzed to identify factors related to LR post-RFA. In the NL and LR groups, the median observation period after treatment was 36.9 months and 33.7 months, respectively. The cumulative LR rates were 5.1%, 11.0%, and 14.2% in the NL group, and 12.8%, 34.2%, and 40.8% in LR group at 1, 3, and 5 years post-RFA, respectively. The Cox proportional hazard test showed that HCC tumors >1.5 cm [hazard ratio (HR)=3.606; p=0.001] and tumor site (adjacent to blood vessels) (HR=1.932; p=0.035) were identified as independent risk factors for LR post-RFA in the NL group, while only TACE prior to RFA was identified in the LR group. Tumor size and site of HCC were independent risk factors for LR post-RFA. Moreover, repeated RFA for LR-HCC post-first RFA had quite a high rate of LR post-RFA. For these cases, the selection of modalities other than RFA should be considered.
- Open Access
- 29 October 2024
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 38 (6) , 2774-2781
WNT/β-catenin Signaling and CD8+ Tumor-infiltrating Lymphocytes in Tremelimumab Plus Durvalumab for Advanced Hepatocellular Carcinoma
Background/Aim: Tremelimumab plus durvalumab is an approved first-line therapy for advanced hepatocellular carcinoma (HCC). Previous studies identified WNT/β-catenin mutations or CD8+ tumor-infiltrating lymphocytes (TILs) as biomarkers that can predict responsiveness to immune checkpoint inhibitor therapy in HCC. However, biomarkers for effectiveness of tremelimumab plus durvalumab in HCC have not been reported. This study investigated whether evaluation of WNT/β-catenin signaling and CD8+ TILs by immunohistochemical staining of tumor biopsy tissues can predict the response to tremelimumab plus durvalumab in patients with HCC. Patients and Methods: Fifteen HCC patients who underwent tumor biopsies were classified into three groups based on WNT/β-catenin signal activation and CD8+ TIL infiltration. The clinical responses to treatment in the groups were evaluated. Results: Four patients had HCC with WNT/β-catenin signal inactivation and high-level CD8+ TIL infiltration, four patients had HCC with WNT/β-catenin signal activation and low-level CD8+ TIL infiltration, and seven patients had WNT/β-catenin signal activation and high-level CD8+ TIL infiltration or WNT/β-catenin signal inactivation and low-level CD8+ TIL infiltration. A better response rate was observed in the WNT/β-catenin signal inactivation and high-level CD8+ TIL infiltration group, and a worse response rate was observed in the WNT/β-catenin signal activation and low-level CD8+ TIL infiltration group. Conclusion: Although the present study involved a small number of patients, the findings suggest that the efficacy of tremelimumab plus durvalumab may be affected by WNT/β-catenin signaling and CD8+ TIL infiltration.
- 29 October 2024
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 38 (6) , 2774-2781
Open AccessWNT/β-catenin Signaling and CD8+ Tumor-infiltrating Lymphocytes in Tremelimumab Plus Durvalumab for Advanced Hepatocellular Carcinoma
Background/Aim: Tremelimumab plus durvalumab is an approved first-line therapy for advanced hepatocellular carcinoma (HCC). Previous studies identified WNT/β-catenin mutations or CD8+ tumor-infiltrating lymphocytes (TILs) as biomarkers that can predict responsiveness to immune checkpoint inhibitor therapy in HCC. However, biomarkers for effectiveness of tremelimumab plus durvalumab in HCC have not been reported. This study investigated whether evaluation of WNT/β-catenin signaling and CD8+ TILs by immunohistochemical staining of tumor biopsy tissues can predict the response to tremelimumab plus durvalumab in patients with HCC. Patients and Methods: Fifteen HCC patients who underwent tumor biopsies were classified into three groups based on WNT/β-catenin signal activation and CD8+ TIL infiltration. The clinical responses to treatment in the groups were evaluated. Results: Four patients had HCC with WNT/β-catenin signal inactivation and high-level CD8+ TIL infiltration, four patients had HCC with WNT/β-catenin signal activation and low-level CD8+ TIL infiltration, and seven patients had WNT/β-catenin signal activation and high-level CD8+ TIL infiltration or WNT/β-catenin signal inactivation and low-level CD8+ TIL infiltration. A better response rate was observed in the WNT/β-catenin signal inactivation and high-level CD8+ TIL infiltration group, and a worse response rate was observed in the WNT/β-catenin signal activation and low-level CD8+ TIL infiltration group. Conclusion: Although the present study involved a small number of patients, the findings suggest that the efficacy of tremelimumab plus durvalumab may be affected by WNT/β-catenin signaling and CD8+ TIL infiltration.
- Open Access
- 26 June 2024
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 28 (3) , 1-7
Diagnostic features of autoimmune hepatitis in SARS‑CoV‑2‑vaccinated vs. unvaccinated individuals
The global coronavirus disease 2019 (COVID‑19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), has affected millions of lives, leading to significant morbidity and mortality. With >772 million cases and nearly seven million deaths reported worldwide to date, the development of vaccines has been a critical step in mitigating the impact of COVID‑19. However, concerns have arisen regarding the potential for SARS‑CoV‑2 mRNA vaccination to trigger autoimmune diseases, including autoimmune hepatitis (AIH). The present single‑center, retrospective study aimed to compare the clinical and pathological features of AIH in patients with or without a history of SARS‑CoV‑2 mRNA vaccination. A total of 72 patients with AIH were examined. Among them, 10 had received the SARS‑CoV‑2 mRNA vaccination prior to AIH onset. These patients exhibited more pronounced CD4+ T cell infiltration into the liver tissue compared with those who were unvaccinated. No significant differences in the levels of other liver enzymes, autoimmune antibodies, or CD8+ T cell infiltration were observed between the groups. Moreover, the AIH patients with a history of SARS‑CoV‑2 mRNA vaccination had more extensive CD4+ T cell infiltration in their liver tissues than the unvaccinated patients. These findings suggested that the immune response to SARS‑CoV‑2 mRNA vaccination may influence the pathogenesis of AIH, highlighting the need for further research into the relationship between SARS‑CoV‑2 mRNA vaccination and autoimmune liver diseases. Such studies will also help clarify the distinction between vaccine‑induced liver injury and traditional AIH.
- 26 June 2024
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 28 (3) , 1-7
Open AccessDiagnostic features of autoimmune hepatitis in SARS‑CoV‑2‑vaccinated vs. unvaccinated individuals
The global coronavirus disease 2019 (COVID‑19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), has affected millions of lives, leading to significant morbidity and mortality. With >772 million cases and nearly seven million deaths reported worldwide to date, the development of vaccines has been a critical step in mitigating the impact of COVID‑19. However, concerns have arisen regarding the potential for SARS‑CoV‑2 mRNA vaccination to trigger autoimmune diseases, including autoimmune hepatitis (AIH). The present single‑center, retrospective study aimed to compare the clinical and pathological features of AIH in patients with or without a history of SARS‑CoV‑2 mRNA vaccination. A total of 72 patients with AIH were examined. Among them, 10 had received the SARS‑CoV‑2 mRNA vaccination prior to AIH onset. These patients exhibited more pronounced CD4+ T cell infiltration into the liver tissue compared with those who were unvaccinated. No significant differences in the levels of other liver enzymes, autoimmune antibodies, or CD8+ T cell infiltration were observed between the groups. Moreover, the AIH patients with a history of SARS‑CoV‑2 mRNA vaccination had more extensive CD4+ T cell infiltration in their liver tissues than the unvaccinated patients. These findings suggested that the immune response to SARS‑CoV‑2 mRNA vaccination may influence the pathogenesis of AIH, highlighting the need for further research into the relationship between SARS‑CoV‑2 mRNA vaccination and autoimmune liver diseases. Such studies will also help clarify the distinction between vaccine‑induced liver injury and traditional AIH.
- 1 November 2023
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 3 (6) , 660-666
Combined Ultrasound and Computed Tomography Guidance in Radiofrequency Ablation for Hepatocellular Carcinoma Reduces Local Recurrence Rate
Background/Aim: In radiofrequency ablation (RFA) treatment of hepatocellular carcinoma (HCC), the therapeutic effect depends on the appropriate position of the electrode. To improve the accuracy of the electrode needle position, we currently perform RFA with combined ultrasound sonography (US) and computed tomography (CT) guidance. The purpose of this study was to evaluate the effectiveness of this US/CT-guided RFA method. Patients and Methods: This retrospective study recruited 97 patients with single tumors treated with transcatheter arterial chemoembolization and monopolar RFA between January 2013 and December 2017. Among these, 50 patients were treated with RFA under US/CT guidance (US/CT-guided group) and 47 were treated with RFA under US guidance alone (US-guided group). We analyzed the efficacy of US/CT guidance compared with US guidance alone. Results: The 1-, 2-, and 3-year local recurrence rates for the US/CT-guided and US-guided groups were 4.1%, 6.3%, and 8.6%, and 19.6%, 31.6%, and 41.9%, respectively. The local recurrence rate was lower in the US/CT-guided group (p=0.0030). Cox proportional hazards model for multivariate analysis demonstrated that the independent risk factors associated with local recurrence were tumor size (p=0.0028) and US/CT guidance (p=0.0037). Conclusion: US/CT-guided RFA for HCC reduced the local recurrence rate compared with US-guided RFA alone.
- 1 November 2023
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 3 (6) , 660-666
Combined Ultrasound and Computed Tomography Guidance in Radiofrequency Ablation for Hepatocellular Carcinoma Reduces Local Recurrence Rate
Background/Aim: In radiofrequency ablation (RFA) treatment of hepatocellular carcinoma (HCC), the therapeutic effect depends on the appropriate position of the electrode. To improve the accuracy of the electrode needle position, we currently perform RFA with combined ultrasound sonography (US) and computed tomography (CT) guidance. The purpose of this study was to evaluate the effectiveness of this US/CT-guided RFA method. Patients and Methods: This retrospective study recruited 97 patients with single tumors treated with transcatheter arterial chemoembolization and monopolar RFA between January 2013 and December 2017. Among these, 50 patients were treated with RFA under US/CT guidance (US/CT-guided group) and 47 were treated with RFA under US guidance alone (US-guided group). We analyzed the efficacy of US/CT guidance compared with US guidance alone. Results: The 1-, 2-, and 3-year local recurrence rates for the US/CT-guided and US-guided groups were 4.1%, 6.3%, and 8.6%, and 19.6%, 31.6%, and 41.9%, respectively. The local recurrence rate was lower in the US/CT-guided group (p=0.0030). Cox proportional hazards model for multivariate analysis demonstrated that the independent risk factors associated with local recurrence were tumor size (p=0.0028) and US/CT guidance (p=0.0037). Conclusion: US/CT-guided RFA for HCC reduced the local recurrence rate compared with US-guided RFA alone.
- Open Access
Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice
In the systemic drug treatment of hepatocellular carcinoma, only the tyrosine kinase inhibitor (TKI) sorafenib was available for a period. This was followed by the development of regorafenib as a second-line treatment after sorafenib, and then lenvatinib, a new TKI, proved non-inferiority to sorafenib and became available as a first-line treatment. Subsequently, cabozantinib, another TKI, was introduced as a second-line treatment, along with ramucirumab, the only drug proven to be predictive of therapeutic efficacy when AFP levels are >400 ng/mL. It is an anti-VEGF receptor antibody. More recently, immune checkpoint inhibitors have become the mainstay of systemic therapy and can now be used as a first-line standard treatment for HCC. However, the objective response rate for these drugs is currently only 30% to 40%, and there is a high incidence of side effects. Additionally, there are no practical biomarkers to predict their therapeutic effects. Therefore, this review provides an overview of extensive research conducted on potential HCC biomarkers from blood, tissue, or imaging information that can be used in practice to predict the therapeutic efficacy of systemic therapy before its initiation.
Open AccessPotential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice
In the systemic drug treatment of hepatocellular carcinoma, only the tyrosine kinase inhibitor (TKI) sorafenib was available for a period. This was followed by the development of regorafenib as a second-line treatment after sorafenib, and then lenvatinib, a new TKI, proved non-inferiority to sorafenib and became available as a first-line treatment. Subsequently, cabozantinib, another TKI, was introduced as a second-line treatment, along with ramucirumab, the only drug proven to be predictive of therapeutic efficacy when AFP levels are >400 ng/mL. It is an anti-VEGF receptor antibody. More recently, immune checkpoint inhibitors have become the mainstay of systemic therapy and can now be used as a first-line standard treatment for HCC. However, the objective response rate for these drugs is currently only 30% to 40%, and there is a high incidence of side effects. Additionally, there are no practical biomarkers to predict their therapeutic effects. Therefore, this review provides an overview of extensive research conducted on potential HCC biomarkers from blood, tissue, or imaging information that can be used in practice to predict the therapeutic efficacy of systemic therapy before its initiation.
- Open Access
- 17 July 2023
- Published by MDPI AG in Preprints.org
Exploration of Practical Biomarkers for Systemic Drug Therapy for Hepatocellular Carcinoma
A number of agents, including immune checkpoint inhibitors, have become available for the treatment of hepatocellular carcinoma (HCC). However, the objective response rate of these drugs is currently only 30% to 40%, with a high incidence of side effects. There are also no prac-tical biomarkers to predict their therapeutic effects. Most of the systemic therapies for HCC are performed in general hospitals without research facilities. Such hospitals can perform imaging tests, like CT and MRI, as well as pathological diagnosis using tumor tissue sampling and im-munohistochemical staining. However, analyzing tumor genomic or transcriptomic profiles is difficult because of limitations in facilities, personnel, and cost. Therefore, in this review, we provide an overview of the wide range of research that has been conducted on HCC biomarkers from blood, tissue, or imaging information that can be used practically in general hospitals for predicting the therapeutic effect of systemic therapies before treatment begins. For general hos-pitals that treat HCC patients, we recommend conducting treatment after assessing the state within the tumor tissue as much as possible by collecting blood and tissue samples and per-forming pre- treatment MRI image evaluations.
- 17 July 2023
- Published by MDPI AG in Preprints.org
Open AccessExploration of Practical Biomarkers for Systemic Drug Therapy for Hepatocellular Carcinoma
A number of agents, including immune checkpoint inhibitors, have become available for the treatment of hepatocellular carcinoma (HCC). However, the objective response rate of these drugs is currently only 30% to 40%, with a high incidence of side effects. There are also no prac-tical biomarkers to predict their therapeutic effects. Most of the systemic therapies for HCC are performed in general hospitals without research facilities. Such hospitals can perform imaging tests, like CT and MRI, as well as pathological diagnosis using tumor tissue sampling and im-munohistochemical staining. However, analyzing tumor genomic or transcriptomic profiles is difficult because of limitations in facilities, personnel, and cost. Therefore, in this review, we provide an overview of the wide range of research that has been conducted on HCC biomarkers from blood, tissue, or imaging information that can be used practically in general hospitals for predicting the therapeutic effect of systemic therapies before treatment begins. For general hos-pitals that treat HCC patients, we recommend conducting treatment after assessing the state within the tumor tissue as much as possible by collecting blood and tissue samples and per-forming pre- treatment MRI image evaluations.
- Open Access
- 24 December 2021
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 16 (2) , 1-10
Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with iso‑high intensity in the hepatobiliary phase of Gd‑EOB‑DTPA‑MRI
Previous studies have reported that hepatocellular carcinoma (HCC) harboring WNT/β‑catenin mutations exhibits iso‑high intensity by gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid‑enhanced magnetic resonance imaging (Gd‑EOB‑DTPA‑MRI, i.e. EOB‑MRI) during the hepatobiliary phase (HBP), thus indicating that EOB‑MRI may help clinicians identify an immune exclusion class, which might not respond to treatment with immune checkpoint inhibitors. The present study analyzed the efficacy of lenvatinib for HCC with iso‑high intensity during the HBP of EOB‑MRI. Overall, 52 patients who underwent EOB‑MRI for 140 HCC nodules were classified into iso‑high‑intensity and low‑intensity groups during the HBP of EOB‑MRI. The clinical and histological characteristics, and different responses to treatment of both groups were analyzed. The expression levels of β‑catenin and glutamine synthetase, indicative of WNT/β‑catenin mutations, were enhanced in the HCC with iso‑high‑intensity group. Nine patients had iso‑high intensity, whereas 43 patients had low intensity. Tumor size was larger, and the levels of antagonist‑II or vitamin K absence were higher in the iso‑high‑intensity group. Furthermore, 3/9 patients in the iso‑high‑intensity group had objective responses compared with 13/43 patients in the low‑intensity group. Disease control was observed in 5/9 patients in the iso‑high‑intensity group and 26/43 patients in the low‑intensity group. Median overall survival was 29.8 months for the iso‑high‑intensity group compared with 20.8 months for the low‑intensity group. In the iso‑high‑intensity group, the median progression‑free survival rate was 6.7 months compared with 5.6 months in the low‑intensity group. No differences in best percentage change from baseline tumor size were observed in either group. Although few patients were included in this study, the present findings suggested that the efficacy of lenvatinib was unaffected by signal intensity during the HBP of EOB‑MRI.
- 24 December 2021
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 16 (2) , 1-10
Open AccessTherapeutic efficacy of lenvatinib for hepatocellular carcinoma with iso‑high intensity in the hepatobiliary phase of Gd‑EOB‑DTPA‑MRI
Previous studies have reported that hepatocellular carcinoma (HCC) harboring WNT/β‑catenin mutations exhibits iso‑high intensity by gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid‑enhanced magnetic resonance imaging (Gd‑EOB‑DTPA‑MRI, i.e. EOB‑MRI) during the hepatobiliary phase (HBP), thus indicating that EOB‑MRI may help clinicians identify an immune exclusion class, which might not respond to treatment with immune checkpoint inhibitors. The present study analyzed the efficacy of lenvatinib for HCC with iso‑high intensity during the HBP of EOB‑MRI. Overall, 52 patients who underwent EOB‑MRI for 140 HCC nodules were classified into iso‑high‑intensity and low‑intensity groups during the HBP of EOB‑MRI. The clinical and histological characteristics, and different responses to treatment of both groups were analyzed. The expression levels of β‑catenin and glutamine synthetase, indicative of WNT/β‑catenin mutations, were enhanced in the HCC with iso‑high‑intensity group. Nine patients had iso‑high intensity, whereas 43 patients had low intensity. Tumor size was larger, and the levels of antagonist‑II or vitamin K absence were higher in the iso‑high‑intensity group. Furthermore, 3/9 patients in the iso‑high‑intensity group had objective responses compared with 13/43 patients in the low‑intensity group. Disease control was observed in 5/9 patients in the iso‑high‑intensity group and 26/43 patients in the low‑intensity group. Median overall survival was 29.8 months for the iso‑high‑intensity group compared with 20.8 months for the low‑intensity group. In the iso‑high‑intensity group, the median progression‑free survival rate was 6.7 months compared with 5.6 months in the low‑intensity group. No differences in best percentage change from baseline tumor size were observed in either group. Although few patients were included in this study, the present findings suggested that the efficacy of lenvatinib was unaffected by signal intensity during the HBP of EOB‑MRI.